InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Share Price

- Current share price for SPL : $0.750

Starpharma Holdings Limited (SPL), an ASX-listed company, is a biotechnology company with over 20 years of experience in developing dendrimer technology for pharmaceutical applications. Their mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of their unique dendrimer technology.

SPL General Information +

ASX Code SPL
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 315
SPL Share Price $0.750
Day High $0.755
Day Low $0.740
Last Close $0.750
SPL Share Price Movement - ( No change )
Prices as at 16:40, 31 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Starpharma Holdings Limited (SPL) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Interim 1.5¢ 100% 25 Mar 1988 15 Apr 1988 - - -

See all dividends from Starpharma Holdings Limited (SPL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Starpharma Holdings Limited (SPL) price-sensitive announcements

SPL - Entitlement Offer Investor Presentation
Starpharma Holdings Limited is launching a fully underwritten approximately A$32 million p
Starpharma Holdings Limited (SPL)
15 Jul 2026 | 9:15 AM
SPL - Fully Underwritten Entitlement Offer to Raise $32 Million
Starpharma Holdings Limited has announced a fully underwritten entitlement offer to raise
Starpharma Holdings Limited (SPL)
15 Jul 2026 | 9:10 AM
SPL - Quarterly Activities Report and Appendix 4C
Starpharma Holdings Limited's Quarterly Activities Report and Appendix 4C for the quarter
Starpharma Holdings Limited (SPL)
15 Jul 2026 | 9:03 AM
SPL - DEP milestone triggers partner option fee
Starpharma Holdings Limited has announced a key milestone in its collaboration with Radiop
Starpharma Holdings Limited (SPL)
3 Jul 2026 | 9:29 AM

Starpharma Holdings Limited (SPL) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Starpharma Holdings Limited (SPL)
ORDINARY FULLY PAID
Health Care $316 Letter to Ineligible Shareholders 23 Jul 2026 4:21PM $0.695 $0.750 risen by 7.91%
Starpharma Holdings Limited (SPL)
ORDINARY FULLY PAID
Health Care $316 Letter to Eligible Shareholders 23 Jul 2026 4:20PM $0.695 $0.750 risen by 7.91%
Starpharma Holdings Limited (SPL)
ORDINARY FULLY PAID
Health Care $316 Ceasing to be a substantial holder 21 Jul 2026 5:50PM $0.700 $0.750 risen by 7.14%
Starpharma Holdings Limited (SPL)
ORDINARY FULLY PAID
Health Care $316 Entitlement Offer Booklet 17 Jul 2026 9:36AM $0.730 $0.750 risen by 2.74%
Starpharma Holdings Limited (SPL)
ORDINARY FULLY PAID
Health Care $316 Cleansing Notice 15 Jul 2026 9:25AM $0.755 $0.750 fallen by 0.66%
Starpharma Holdings Limited (SPL)
ORDINARY FULLY PAID
Health Care $316 Proposed issue of securities - SPL 15 Jul 2026 9:20AM $0.755 $0.750 fallen by 0.66%

SPL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$9.99 -$2.30 20.70% 0.00 0.00 0.00% 0.0%
2024A -$8.17 -$1.90 -48.10% 0.00 0.00 0.00% 0.0%
2023A -$15.64 -$3.70 -3.90% 0.00 0.00 0.00% 0.0%

SPL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Clarity Pharmaceuticals Ltd (CU6) $783M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,216M -0.7857 0.0743 1.2000 75.1182 69.9200 31.7818 0.00% 0.00% 0.00%
Starpharma Holdings Limited (SPL) $316M 0.2073 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

SPL Directors

Name Position Start Date
Ms Cheryl Ann Maley Chief Executive Officer, Managing Director 8 Jan 2024
Mr David McIntyre Non-Executive Director 1 Mar 2020
Ms Lynda Cheng Non-Executive Director 1 Aug 2021
Dr Jeff Davies Non-Executive Director 1 Apr 2022
Dr Russell Basser Non-Executive Director 20 Feb 2023
Mr Robert Bain Thomas Non-Executive Director, Non-Executive Chairman 4 Dec 2013

Starpharma Holdings Limited (SPL) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
16 Oct 2025 THOMAS, Robert Buy Direct Shares 450,000 $0.279 $125,471.000
5 Nov 2024 THOMAS, Robert Buy Direct Shares 300,000 $0.093 $28,000.000
23 Oct 2024 THOMAS, Robert Buy Indirect Shares 300,000 $0.093 $27,750.000

See all changes in directors' interest & trades for Starpharma Holdings Limited (SPL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

SPL Management

Name Position
Justin Cahill Chief Financial Officer,Company Secretary

SPL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Starpharma Holdings Limited (SPL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
48,480,000 (11.80%) Allianz SE and the entities
29,838,184 (7.10%) Robmar Investments Pty Umited
26,680,974 (6.40%) ICM Investment Management Ltd

SPL Calendar of Events

Date Event
17 February 2027 Report (Interim)
25 August 2026 Report (Annual)
25 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.